Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Children diagnosed with ulcerative colitis have a good chance of attaining remission after 1 year of treatment with azathioprine or 6-mercaptopurine, according to…
NEW YORK (Reuters Health) – An updated guideline from the American Academy of Neurology recommends plasmapheresis for severe relapses in multiple sclerosis and other inflammatory demyelinating neurologic disorders.…
NEW YORK (Reuters Health) – Depending on the particular regimen, insulin analogs can help 35% to 64% of patients with type 2 diabetes achieve the recommended hemoglobin A1C…
NEW YORK (Reuters Health) – In the emergency department, successful intubation on the first try is equally likely using either succinylcholine at a median dose of 1.65 mg/kg…
NEW YORK (Reuters Health) – In a small study of pregnant women with type 1 diabetes, use of a closed-loop insulin delivery system (also known as the artificial…
NEW YORK (Reuters Health) – Patients with ST-elevation myocardial infarction (STEMI) who present 12 to 24 hours after onset of symptoms should be considered for reperfusion by primary…
NEW YORK (Reuters Health) – A dexamethasone intravitreal implant is more likely to reduce inflammation and improve vision than a sham treatment in patients with noninfectious uveitis, investigators…
NEW YORK (Reuters Health) – A new meta-analysis shows adjunctive subcutaneous omalizumab may help patients with uncontrolled allergic asthma withdraw from or cut back on corticosteroids. Researchers also…
NEW YORK (Reuters Health) – During the first year after coronary artery bypass grafting (CABG), patency rates are similar for radial artery grafts and saphenous vein grafts, study…
NEW YORK (Reuters Health) – For conversion of recent-onset atrial fibrillation, vernakalant acted more rapidly and was more effective than amiodarone in an international study. As reported in…
